Literature DB >> 10656642

F-18 FDG uptake in breast infection and inflammation.

S M Bakheet1, J Powe, A Kandil, A Ezzat, A Rostom, J Amartey.   

Abstract

PURPOSE: Whole-body fluorine-18 fluorodeoxyglucose (F-18 FDG) positron emission tomography (PET) scanning has been useful in the management of breast cancer. However, F-18 FDG uptake sometimes has been associated with benign breast disease. Four cases are reported of F-18 FDG breast uptake caused by infectious or inflammatory mastitis that mimics malignant disease. METHODS AND
RESULTS: Two women had F-18 FDG whole-body scans for the evaluation of a large breast mass after inconclusive results of ultrasonography. In both cases, intense focal F-18 FDG breast uptake was noted that mimicked breast cancer. Histologic examination showed, in one patient, chronic granulomatous infiltration that likely represented tuberculous mastitis, because she showed a good clinical response to empirical anti-tuberculous treatment. The second patient had lactational changes associated with acute inflammation, and the culture grew Staphylococcus aureus. The breast mass completely disappeared 3 weeks after a course of antibiotic treatment. The other two patients had staging F-18 FDG PET scans 1 and 12 months after lumpectomy for breast carcinoma to detect residual, recurrent, or metastatic disease. Both scans showed a ring-like uptake in the involved breast, with superimposed intense focal uptake suggesting tumor necrosis centrally and malignant foci peripherally. In both cases, histologic examination revealed hemorrhagic inflammation secondary to postsurgical hematomas and no evidence of malignancy.
CONCLUSION: Acute or chronic infectious mastitis and postsurgical hemorrhagic inflammatory mastitis should be considered in patients who have a breast mass, especially those with a history of tenderness or surgery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10656642     DOI: 10.1097/00003072-200002000-00003

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  14 in total

1.  [Functional and molecular imaging of breast tumors].

Authors:  K Pinker; P Brader; G Karanikas; K El-Rabadi; W Bogner; S Gruber; M Reisegger; S Trattnig; T H Helbich
Journal:  Radiologe       Date:  2010-11       Impact factor: 0.635

2.  [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer.

Authors:  Ehab M Kamel; Matthias T Wyss; Mathias K Fehr; Gustav K von Schulthess; Gerhard W Goerres
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-12       Impact factor: 4.553

3.  False-positive (18)F-fluorodeoxyglucose positron emission tomography/computed tomography caused by incidental injury in a bulky intracystic carcinoma of the breast.

Authors:  Sachiko Kiyoto; Yoshifumi Sugawara; Takeshi Inoue; Daisuke Takabatake; Shozo Ohsumi; Rieko Nishimura
Journal:  Jpn J Radiol       Date:  2010-05-29       Impact factor: 2.374

4.  Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer.

Authors:  D L Francis; D Visvikis; D C Costa; T H A Arulampalam; C Townsend; S K Luthra; I Taylor; P J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-09       Impact factor: 9.236

5.  In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography.

Authors:  D L Francis; A Freeman; D Visvikis; D C Costa; S K Luthra; M Novelli; I Taylor; P J Ell
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

6.  Recombinant peptides as biomarkers for tumor response to molecular targeted therapy.

Authors:  Ralph J Passarella; Li Zhou; John G Phillips; Hongmei Wu; Dennis E Hallahan; Roberto Diaz
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

7.  Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer.

Authors:  D Visvikis; D Francis; R Mulligan; D C Costa; I Croasdale; S K Luthra; I Taylor; P J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

8.  Clinical Evaluation of Efficacy of (99m)TC -Ethambutol in Tubercular Lesion Imaging.

Authors:  Namrata Singh; A Bhatnagar
Journal:  Tuberc Res Treat       Date:  2010-11-02

Review 9.  Positron emission tomography imaging in sarcoidosis.

Authors:  Beth Vettiyil; Nikitha Gupta; Rajesh Kumar
Journal:  World J Nucl Med       Date:  2013-09

10.  Spectrum of the Breast Lesions With Increased 18F-FDG Uptake on PET/CT.

Authors:  Aisheng Dong; Yang Wang; Jianping Lu; Changjing Zuo
Journal:  Clin Nucl Med       Date:  2016-07       Impact factor: 7.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.